Resisten klorokuin merupakan masalah penanggulangan malaria di Indonesia, terutama di Papua. Dalam 
Since the 1950s, chloroquine has been the most extensively used antimalarial for uncomplicated malaria. It has the advantage of being widely available, cheap, well tolerated and safe. 1 Drug resistant strains of P. falciparum first emerged in Cambodia in 1959 2, 3 and subsequently spread throughout Asia and Africa. Resistance of P. falciparum to chloroquine therapy was first noted in Indonesia almost 30 years ago, 4 and has now been documented through out the country [5] [6] [7] with the highest prevalence reported from northern Papua. 8 Declining efficacy has also been noted to the second therapy of sulfadoxine-pyrimethamine (SP). 9, 10 The emergence of drug resistant strains of P. vivax was only described in 1989 in northern Papua province (formerly Irian Jaya). 11 Other studies of P. vivax have subsequently confirmed a high prevalence of chloroquine resistance in Sumatra, and Northern Papua [8] [9] [10] and elsewhere in Indonesia. 12 Resistance to SP has also been noted. 9 P. ovale and P. malariae account a minor number of cases of malaria, although in some regions their prevalence in symptomatic patients can reach as high as 10%. 5 Few studies have addressed the efficacy of chloroquine to these strains. A recent study in South Sumatra did however indicate the resistant strains of P. malariae may be emerging. 7 In Mimika district on the Southern part of Papua, malaria transmission is unstable and causes an appreciable burden of disease despite an extensive malaria control programme. A small unpublished study in 2001 reported that the day 28 cure rate for P. falciparum had fallen to 21% following sulfadoxinepyrimethamine alone and 25% for chloroquine plus sulphadoxine-pyrimethamine (Crouch-Chivers, personal communication). Failure rates of chloroquine monotherapy for vivax malaria in Timika are unknown, however in the same study chloroquine three days plus a single dose of sulfadoxine-pyrimethamine and primaquine on day 0 resulted in a day 28 cure rate of 25 %.
As part of a series of studies to rationalize antimalarial protocols in this region we undertook a series of chemotherapeutic trials to evaluate and to determine the efficacy of prevailing protocols for uncomplicated malaria.
MATERIALS AND METHODS

Study Site
The study was carried out at an established rural outpatient clinic west of Timika town in Southern Papua (formerly Irian Jaya), Indonesia. This forested lowland area has unstable malaria transmission associated with three mosquito vectors: Anopheles koliensis, An. farauti and An. Punctulatus. 13, 14 The annual incidence of malaria is 620 per 1000 per year, divided 55:45 between P. falciparum and P. vivax infections. In recent surveys of healthy school children the prevalence rate for P. falciparum was 3.3% (203/6173) and that of P. vivax 2.9% (177/6173) -(Peter Ebsworth, personal communication). Due to economic migration the ethnic origin of the local population is diverse, with highland Papuans, lowland Papuans and non Papuans all resident in the region. In view of the high number of infections in non immune patients, local protocols recommend that all patients with patent parasitaemia be given antimalarial therapy irrespective of whether they have symptoms or not.
Study Design
This was a prospective open label without randomization drug efficacy study of existing drugs recommended in 2004 for infections with P. falciparum (chloroquine with sulfadoxine-pyrimethamine), P. vivax (chloroquine), P. ovale (chloroquine) or P. malariae (chloroquine) in children and adults with uncomplicated symptomatic malaria. The study was based on the 2003 World Health Organization (WHO) in vivo antimalarial drug sensitivity protocol, 15 modified to include mixed infections. Patients were followed for 42 days in the falciparum malaria and 28 days for other species of infection.
Patients
Consecutive patients with slide-confirmed malaria of any species and fever or a history of fever during the preceding 48 hours presenting to the outpatient clinic were enrolled in the study if they or their parents gave informed consent. Pregnant or lactating women, children under 10 kg, patients with signs of severity, 16 a parasitaemia >4%, or concomitant disease requiring hospital admission were all excluded. Informed consent was given by an adult patient or by a parent/guardian for children. If the subject was illiterate, consent was obtained in the presence of a literate witness. All patients were given an information sheet in their own language.
Study Procedures
On admission a standardized questionnaire was completed recording demographic information and details of symptoms and their duration and the history of previous antimalarial medication. A full clinical examination was made and the axillary temperature measured using a digital electronic thermometer. Blood was taken for blood film, haematocrit, and white cell count. Parasite counts were determined on Giemsa-stained thick films as the number of parasites per 200 white blood cells (WBC). All slides were read by a certified microscopist with 10 years experience. A thick smear was considered negative on initial review if no parasites were seen in 100 high power fields. A thin smear was also examined to confirm parasite species and used for quantification if parasitaemia was greater than 200 per 200 WBC. All slides were cross checked by another experienced microscopist. Upon cross checking the whole field was checked before a slide was considered negative.
All patients were examined daily thereafter until they became afebrile and aparasitaemic. At each visit a blood smear was taken and a symptom questionnaire completed. Patients were then seen weekly or on any other day when the patient was sick for 4 weeks (P. vivax, Povale, P. malariae infections) or 6 weeks (P. falciparum or mixed infections). At each clinic appointment a full physical examination was performed, the symptom questionnaire was completed, and blood was taken to check for parasite count and haemoglobin level using a battery operated portable photometer (HemoCue Hb201+ ™). Blood spots on filter paper (Whatman 3MM Chromatography Paper) were also collected on day 0 and the day of failure, therefore we can distinguish between reinfection and recrudescence infection with the polymerase chain reaction (PCR).
Plasma Chloroquine Levels
Heparinized venous blood samples were taken from patients who agreed to be venesected on days 0, 7, 28 or the day of recrudescence. Samples were processed within 4 hours of venesection, spun at 2000 rpm for 10 minutes and plasma removed and stored at -20 0 C until analysed. Plasma drug levels of chloroquine (CQ) and its major metabolite desethylchloroquine (DCQ) were assayed by high performance liquid chromatography as described previously. The minimum effective concentration (MEC) of chloroquine plus desethylchloroquine (CQ+DCQ) for P. falciparum was defined as 30 ng/ml plasma and 15ng/ml for P. vivax.
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Treatment
Standard treatment courses of CQ+SP for P. falciparum (alone or mixed with P. vivax), and CQ for pure P. vivax, P. ovale or P. malariae infections were administered. The CQ+SP regimen consisted of CQ (CQ: P.T Bayer, Jakarta, Indonesia-150 mg base /tablet, 25 mg/kg over 3 days) and SP was given as a single dose on day 0 (25 and 1.25 mg/kg, respectively). All drug administrations were supervised and participants observed for 30-60 minutes to exclude adverse reactions and to ensure the medication was not vomited out. If vomiting occurred within 60 minutes the whole dose was repeated once. If vomiting occurred again within 60 minutes the patient was withdrawn from the study. If the axillary temperature was ≥38°C, paracetamol was given.
Treatment failures were retreated with quinine (10mg of salt /kg body weight/dosage orally 3 times a day for 7 days) plus doxycycline (100 mg bd for 7 days) if ≥8 years age and not pregnant. From May 2004 those patients with reappearance of P. vivax within 28 days were given a 3 day course of supervised amodiaquine if they consented (Flavoquine™: Aventis -153 mg base /tablet, 30 mg/kg over 3 days). Primaquine (0.5 mg of base/kg of body weight for 14 days) was administered to those individuals with P. vivax or P. ovale infection or mixed infection on day 28 of their participation in the study.
Endpoints
Therapeutic response was determined using clinical and parasitological criteria. The primary endpoints were the therapeutic response on the basis of parasitological and clinical cure by day 28 for P. vivax, P. ovale or P. malariae infections and day 42 for P. falciparum infection. The criteria, based on 2003 WHO protocol, 15 were modified to include P. falciparum genotyping to differentiate recrudescence from reinfection. The latter was distinguished according to polymorphisms in Merozoite Surface Proteins-1 (MSP-1), Merozoite Surface Proteins-2 (MSP-2) and Glutamaterich Protein (GLURP), before and after antimalarial drug treatment. 18 New infections detected by genotyping were classified as nontreatment failures. New infections and indeterminant Polymerase Chain Reaction (PCR) results were excluded from the day 28 or 42 failure rate if the follow up was terminated before endpoint was achieved. Since chloroquine concentrations persist at levels above the MEC for P. vivax beyond 28 days, 19 any recurrence within this time were considered to be therapeutic failures.
Statistical analysis
Data were analysed using SPSS for Windows (SPSS Inc, Chicago, Illinois). The Mann-Whitney U test or Kruskal-Wallis method was used for nonparametric comparisons, and Student's t-test or one-way analysis of variance for parametric comparisons. For categorical variables percentages and corresponding 95% confidence intervals (95%CI) were calculated using Wilson's method. Proportions were examined using χ 2 with Yates' correction or by Fisher's exact test.
Ethics
The study was approved by the Ethics Committee of the National Institute of Health Research and Development, the Indonesian Ministry of Health (Jakarta, Indonesia), the Ethics committee of Menzies School of Health Research (Darwin, Australia). Informed consent was obtained from all adult participants and from parents of children.
RESULTS
Between April 2004 and August 2005, 207 patients were enrolled in the study. Of these 103 patients were infected with P. falciparum (n=88) or P. falciparum and P. vivax infections (n=15) and treated with chloroquine plus sulfadoxine-pyrimethamine (CQ+SP). The remaining 104 patients were infected with single species infections (P. vivax n=40, P. malariae n=50, P. ovale n=14) and were treated with chloroquine monotherapy. Baseline characteristics are given in table 1.
Demographics Details
Patients with P. vivax or mixed infections of P. falciparum / P. vivax were significantly younger with 27% (15 of 55) being under 5 years of age compared to 9% (14 of 152) of those with other species of infection (see Although all patients presented with a history of fever, only 25% (51 of 207) actually had a recorded fever on admission. Patients with P. falciparum (alone or mixed) were at significantly greater risk of fever compared to non falciparum malaria. Of those patients presenting with a fever 94% (33 of 35) had defervesced by day 2.
Late Therapeutic Response
Recurrence of infection during recovery was observed in 88 patients: 48 of whom had P. falciparum, 29 had P. vivax and 11 had mixed infections ( figure 1) . Overall failure rates were defined as either early treatment failure or the recurrence of the same species after treatment (either alone or mixed). Failure rates after P. falciparum and P. vivax infections were high (table 3) . By day 42 73% (41 of 56) of pure P. falciparum and 77% (10 of 13) of mixed infections had failed treatment. P. vivax infections were followed up for 28 days prior to administration of primaquine. By this time 73% (22 of 30) had failed therapy. Although recurrence of P. falciparum and P. vivax occurred in 34% (22 of 64) with P. malariae or P. ovale infections, there was no occurrence of treatment failure with the same species.
Parasite genotyping was successful and informative in 70% (24 of 41) of the late P. falciparum or mixed isolates and identified 19 true recrudescence and 10 new infections, with indeterminate results in 21 cases. Therefore the polymerase chain reaction (PCR) corrected cure rate of P. falciparum by day 42 was 48% [95%CI :36-66].
Chloroquine levels
On admission plasma chloroquine levels were available in 89 patients of whom 39% (35 of 89) patients had chloroquine detected. At the time of recrudescence of P. falciparum or P. vivax 83% (25 of 30) of those tested had detectable chloroquine concentrations in their blood (median= 82.0 ng/ml [range: 10-242]). Of these patients 61% (14 of 23) of those with P. falciparum had plasma levels above the MEC (30 ng/ml) and 100% (7 of 7) of those with P. vivax had plasma levels above the MEC (15 ng/ml).
Gametocyte Carriage and Anaemia
On admission gametocytes were present in 26% (31 of 119) of non falciparum malaria compared to only 8% (7 of 88) of patients with pure falciparum malaria (table 1, p=0.001). However during follow up only 0.8% (1 of 119) of patients infected with non falciparum malaria had patent gametocytaemia, compared to 46% (32 of 70) after falciparum malaria on day 7 and 45% (24 of 53) on day 14.
On the day of admission anemia (HB under 10 g/dl) were present in 48% (100 of 207) of patients. Patients with P. malariae were at higher risk of anaemia compared to those with other species (p=0.001).
Furthermore patients who failed therapy were 2.2 fold [95%CI 1.1-4.3] more likely to be anaemic on day 7 irrespective of initial species (p=0.03).
Re-treatments
Overall 52 patients had P. falciparum or mixed infections detected during follow up requiring retreatment, of whom 24 (46%) adults and 28 (54%) children (less than 14) agreed to be reenrolled for further follow up. Adults received an unsupervised 7 day course of quinine plus doxycycline, however by day 28 57% (8 of 14) had had a further recurrence of P. falciparum. Children were retreated with 7 days unsupervised quinine and by day 28, 76% (19 of 25) had failed therapy again.
Of the 20 patients with P. vivax infection during follow up, 12 patients were treated with supervised amodiaquine and 6 patients with unsupervised quinine. Only 8 were successfully followed to day 28 after treatment: 3 following amodiaquine and 5 following quinine therapy. There were four further treatment failures, 3 after quinine and 1 after amodiaquine.
DISCUSSION
Since 2004, the combination of artesunate-amodiaquine has become the drug of choice for uncomplicated malaria in Indonesia. However, prior to policy change the majority of uncomplicated infections were still treated with chloroquine (CQ) in Timika, Papua. We therefore evaluated the therapeutic efficacy of the existing antimalarial drugs in symptomatic patients with uncomplicated falciparum and vivax malaria in Timika using the 1997 WHO guidelines. Patients were treated with chloroquine and sulfadoxine-pyrimethamine (SP) for uncomplicated malaria falsiparum and followed for 42 days. Patients with uncomplicated malaria due to other species (P. vivax, P. ovale, or P. malariae) were given chloroquine monotherapy and followed for 28 days before receiving a 14 day course of unsupervised primaquine (P.vivax or P.ovale). Patients failing therapy received unsupervised oral quinine +/-doxycycline for 7 days.
During the execution of this study, we were also able to evaluate the efficacy of amodiaquine in a relatively small number of patients with reappearance of uncomplicated vivax malaria.
In this rural area uncomplicated malaria was observed more in males (60%) and in Papuan (65%) people. This may reflect the greater exposure of adult males and non Papuans to areas of malaria transmission. Symptomatic malaria occurred in all age groups in keeping with the high proportion of non immune individuals in this area.
The cumulative day 28 failure rate for P.falciparum was 59% compared to and 77% for pure vivax infections. After correcting for reinfection by PCR the day 42 failure rate for P. falciparum was 62% [95% CI: 47-74]. These high rates of late treatment failure were associated with extremely poor early therapeutic response with 4% of patients with falciparum malaria and 16% of patients with P. vivax requiring rescue therapy. Retreatment with an unsupervised course of quinine +/-doxycycline was associated with an equally poor outcome. By day 28,57% of patients with a recurrence parasitaemia retreated with quinine plus doxycycline failed therapy again and this figure rose 76% in children who were treated with quinine alone. Quinine treatment was unsupervised and although the poor efficacy could be attributable to quinine resistance a more likely explanation is poor adherence to a difficult regimen (three times daily for 7 days) which is frequently associated with unpleasant side effect (cinchonism, nausea and dizziness ). Although a study of supervised therapy would help to resolve this, in practice supervision is not an option and hence the usefulness of this regimen appears limited in uncomplicated malaria.
In total 11 patients with recrudescent P. vivax were retreated with amodiaquine monotherapy. Early parasite clearance was rapid in all cases with no early treatment failures. Although only three patients were followed for 28 days no failure of therapy was found during this time. This is one of the first reports of the efficacy of amodiaquine against chloroquine-resistant strains.
Although it suggests that its efficacy may be superior to chloroquine, further studies are needed to confirm this.
In contrast to the poor efficacy of P. falciparum and P. vivax there were no early treatment failures when chloroquine was used alone for P. malariae malaria or P. ovale infections. Although late treatment failures did occur (18 following P. malariae and 6 following P. ovale), none of these were with the same species, suggesting either reinfection or recrudescence from pre-patent parasitaemias in the initial infection. Hence the success rate of either of these species to chloroquine remains at 100%.
Alternative treatment regimens in this region are clearly needed. The World Health Organisation (WHO) recommends the use of artemisinin combination therapy (ACT) in regions where antimalarial drug resistance is emerging. Artemisinin derivatives have been shown to be safe and effective against both drug resistant falciparum and vivax malaria. Current national recommendations advocate the use of a combination of artesunate and amodiaquine, although alternative regimens, such as artemether-lumefantrine and dihydroartemisinin-piperaquine are also available. Further studies are in progress to determine the relative efficacy of these new combination therapies.
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